| Project/Area Number |
26461604
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Department of Clinical Research, National Hospital Organization Kanazawa Medical Center |
|---|
Principal Investigator |
Maeba Hideaki 独立行政法人国立病院機構(金沢医療センター臨床研究部), その他部局等, その他 (10419335)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 制御性樹状細胞 / PUVA / GVHD / 移植片対宿主病 |
|---|
| Outline of Final Research Achievements |
Bone marrow-derived cultured DCs acquired tolerogenicity by PUVA (psoralen+UVA) treatment in mice. In vitro assays, strong tolerogenicity was observed when adding PUVA-DC even from third party strain into MLR. That is, the PUVA-DC have tolerogenic function in a MHC-independent manner. We showed that cell-to-cell contact was needed to mediate the regulatory effect by transwell experiment. Next, we compared the expression of the IDO, which induces T-cell anergy, by real-time PCR between PUVA-DC and BM-DC. An increase IDO gene transcription level was observed in PUVA-DC about 5 times more than in BM-DC. But adding 1-MT, which is an inhibitor of IDO, had no effects on MLR with PUVA-DC.
We transfused PUVA-DC (Host-type, Donor-type, Third-party-type) in a mouse GVHD model, but the GVHD inhibitory effects were not observed. It was thought the survival of PUVA-DC was insufficient. These data leads us to search for technique to make PUVA-DC to survive after in vivo administration.
|
